A phase I trial of ATA-188-Autologous in multiple sclerosis

Trial Profile

A phase I trial of ATA-188-Autologous in multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs ATA 188 Autologous (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Oct 2017 Results will be presented at the MSParis 2017 Congress, the 7th Joint Meeting of ECTRIMS and ACTRIMS, according to an Atara Biotherapeutics media release.
    • 07 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to an Atara Biotherapeutics media release.
    • 31 Jul 2017 According to an Atara Biotherapeutics media release, results from this trial (n = 6) were presnted at the American Academy of Neurology (AAN) meeting in April 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top